Weight loss jab Wegovy could lower your risk of dementia
Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person's risk of dementia, a new study suggests.
Researchers found these medications show promise in lowering the risk of cognitive impairment.
Experts say further research is needed to understand the drugs' effects on the brain and the mechanisms behind this potential protective effect.
The US study analysed data from type 2 diabetes patients taking either GLP-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter-2inhibitors (SGLT-2i).
GLP-1RAs like semaglutide work by suppressing appetite, while SGLT-2i reduce glucose reabsorption in the kidneys.
Semaglutide is available as Wegovy and Ozempic injections, and also as Rybelsus tablets.
The study's findings indicate a potential link between these medications and a lower risk of dementia.
Wegovy was approved to tackle weight loss on the NHS in 2023, while Ozempic and Rybelus are available on the health service as treatments for type 2 diabetes.
The study examined the health records of 396,963 people from the OneFlorida+ Clinical Research Consortium between January 2014 and June 2023.
All patients were aged over 50 and had type 2 diabetes. They had no diagnosis of Alzheimer's disease and related dementias (ADRD).
Researchers compared those on GLP-1RAs, SGLT-2i and other, second-line glucose-lowering drugs.
The analysis found that 'both GLP-1RAs and SGLT2is were statistically significantly associated with decreased risk of ADRD compared with other GLDs, and no difference was observed between both drugs'.
Meanwhile, among the GLP-1RAs, 'semaglutide seems to be promising in reducing the risk of ADRD'.
'This finding is particularly intriguing given the existing research on semaglutide's neuroprotective properties,' researchers said.
Dr Leah Mursaleen, head of clinical research at Alzheimer's Research UK, said: 'The results from this study support the growing evidence that GLP-1RA and SGLT-2 inhibitors medicines may reduce dementia risk.
'We don't know yet why these medicines may be offering a protective effect, and will need more research to understand how they are affecting the brain.'
She added that while the findings are 'interesting', it is important to consider if other factors might be influencing results like overall health, income or education.
Meanwhile, researchers in Ireland suggested GLP-1RAs are 'associated with a statistically significant reduction in dementia'.
The study analysed 26 clinical trials involving almost 165,000 patients to determine if drugs like SGLT2is and GLP-1RAs, as well as diabetes medications metformin and pioglitazone, led to a reduction in risk of dementia or cognitive impairment.
It found most drugs 'were not associated with an overall reduction in all-cause dementia' although 'GLP-1RAs was associated with a statistically significant reduction in all-cause dementia'.
Both studies have been published in the journal Jama Neurology.
Prof Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh, group leader in the UK Dementia Research Institute, and president of the British Neuroscience Association, said the data is 'encouraging' for the 'potential of using GLP-1Ras to lower dementia risk in people with diabetes'
'But even within these two strong studies, there are slightly conflicting results over SGLT2is highlighting the need for further research,' she added.
'It is important to note that these drugs do have side effects and that they are not guaranteed to prevent dementia.
'The studies had important limitations including a relatively short follow up time. Future work will be important to understand how risk factors like diabetes and obesity increase risk of dementia to develop effective treatments and prevention strategies.'
Masud Husain, a professor of neurology and cognitive neuroscience at the University of Oxford, added: 'For me, these new retrospective analyses suggest that GLP-1 receptor agonists, particularly semaglutide, might reduce the risk of developing dementia in people with type 2 diabetes.
'But we need data from prospective trials to provide stronger evidence.
'The wider question of whether such drugs might also be protective against dementia in people who don't have diabetes is a really intriguing one, and the focus of several ongoing clinical trials.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
33 minutes ago
- BBC News
Hospitals to get £2.6m for 'urgent' infrastructure upgrades
Several hospitals are set to get upgrades after Nottinghamshire Healthcare NHS Foundation Trust has secured government will include improving fire safety systems, water infrastructure and electrical and energy systems at Rampton Hospital, The Wells Road Centre, Wathwood Hospital, Thorneywood Mount and Arnold Lodge improvements at the sites, which offer mental health and community services across the Midlands and South Yorkshire, are due to start in the summer with the aim of completing next Healthcare NHS Foundation Trust, which runs the hospitals, said the funding would support urgent projects and create a better environment for patients. The £2,595,000 grant is part of a national project to improve NHS buildings and infrastructure in Rampton High Secure Hospital and several others, it is hoped the money will allow a full upgrade of fire safety systems - including alarms, fire compartmentation and suppression Wells Road Centre in Mapperley, Nottingham, will benefit from the replacement of ageing at Arnold Lodge, in Leicester, a specialist secure unit, the money will deliver electrical and energy system improvements. The trust said planning work was under way to ensure the disruption was executive at the trust Ifti Majid said the funding was "fantastic news", adding: "It allows us to fast-track improvements that make our hospitals safer, greener and more welcoming places to receive care and to work."Alison Wyld, executive director of finance and estates, added: "By tackling our highest-risk infrastructure now, we're not only reducing future maintenance costs but also supporting the trust's net zero ambitions."
Daily Mirror
an hour ago
- Daily Mirror
'I'm a dietitian and this is what I have for breakfast, lunch and dinner'
You'll be glad to know her diet includes chocolate! A dietitian has revealed her typical daily meals - from breakfast to dinner, including dessert. Josie Porter, known as @thedietitianmethod on TikTok, follows one key principle: avoiding ' weird food rules.' As a registered dietitian, she completed her training at several leading NHS trusts in London. Porter, BSc MSc RD, introducing the video, saying: 'This is everything a dietitian eats in a day with no weird food rules.' Because it's the weekend, she decided to go on a run and fueled up on a banana before heading out. After she came back, she then had her "proper breakfast". She makes a delicious pistachio tiramisu granola bites with a mascarpone base, calling the dish "up there with one of my favorite variations." Next, she has her lunch which consists of boiled eggs, lots of chilli oil, edamame beans and spring onions. She has this all together on a chopping board and chops it all up and stuffs it into a soft pitta. When it comes to dinner, she enjoys variety and colour. She chose jerk salmon, kidney beans, coriander rice, and a cashew and mango slaw. Speaking about her dinner, she says: "It has everything you need from fiber, protein, flavour and the juicy mango." And to end the day, she tucks into some chocolate. Dietitian's diet - breakfast, lunch, dinner and dessert Pre-run food: One banana Breakfast: Pistachio tiramisu granola bites with a mascarpone base Lunch: Boiled eggs, chilli oil, edamame beans and spring onions in a soft pitta Dinner: Jerk salmon with a cashew and mango slaw, kidney beans and coriander rice Dessert: Chocolate Pistachio tiramisu granola bites with a mascarpone base - how to make In a separate video, the food expert said she loves to "make a batch ahead of time and store in the fridge". It's "ideal for brunch spreads, breakfast on-the-go, or when you want a little snack that still offers some nutritional oomph." Ingredients serves 1, double for 2 etc... 1 ripe banana 30g rolled oats 2 tbsp chopped pistachios 1 tbsp maple syrup (optional, for sweetness) 1 tsp instant espresso or coffee powder 1 tsp cacao powder Pinch of salt 2 tbsp Greek yogurt (full fat works best, but any does the trick!) 1 tbsp mascarpone Cocoa powder (for dusting) Optional: pistachio butter for drizzling Method Preheat oven to 180°C fan if using over an airfryer. Skip this step if using an air fryer. In a bowl, mash the banana with espresso powder, salt, and cacao powder, then mix in oats, maple syrup (if using), vanilla, and pistachios. Onto baking paper, add all and press flat with a fork or spoon. Bake for 10 mins in air fryer on 180, or 15–18 mins in oven until just golden. Meanwhile, mix the Greek yogurt and mascarpone until smooth and creamy. Add maple syrup if you want it sweet. Place into your serving bowl as your base. Once your bites have cooled slightly, scrap into clusters with a spoon or fork. Then crumble over the creamy base, dust with cocoa powder, and finish with pistachio butter (if using!)
Glasgow Times
3 hours ago
- Glasgow Times
Weight-loss jabs may need to be taken for life, experts warn
The drugs are sold under brand names like Mounjaro and Wegovy and work by reducing food cravings. Obese patients can currently be prescribed the jabs on the NHS after being referred to specialist weight loss clinics, which are usually located in hospitals. Hundreds of thousands of people also access the medication privately at pharmacies. There have been warnings about buying potentially unsafe jabs online from unregulated retailers and potentially missing out on wraparound support. Experts said the jabs should not be seen as the first option in weight loss and should be used in conjunction with lifestyle changes, such as eating more healthily and increasing exercise. Professor Graham Easton, a GP who has been using weight loss jabs himself, said: 'I think it's a major issue about the proper funding and resourcing of not only the GPs in the surgeries but also the wraparound care we talked about. 'I think the other issue is that so far, to my knowledge, the NHS and National Institute for Health and Care Excellence have talked about this being something you take for two years, and that's probably related to data from research studies. 'But as we discussed, this is likely to be a lifelong commitment if it is going to be worthwhile to the NHS. 'There's no point in most people taking it for a couple of years and then have the weight bouncing back. 'You can argue possibly you're about to prepare for surgery or something, but in most cases it doesn't make any sense. 'Then I think there's a big issue around access. Most obesity occurs in poorer populations as wealthier populations tend to not be so affected. 'There's a massive sort of socio-economic inequality and there is a worry about this driving that inequality even further. 'Unless the NHS makes sure that these are available across the board equally, I think that's a major risk.' Prof Easton said recent studies had shown people who stopped taking the drugs had put the weight they lost back on within around a year. 'That's often true of any diet, people would say, and that's certainly my experience of having wrestled with my weight in diets over the years,' he said. 'All I would say that I found interesting from that review was that they were suggesting perhaps that weight returns even quicker after having been on GLP-1 drugs. 'Then speculating, because there was no way of knowing from that review, that perhaps it's because people are not changing the behaviours we've been talking about like exercise and other lifestyle changes, just relying on the drugs. 'When you stop them, of course, you're going to put weight back on. The switch is turned back off, or whatever it was. 'I mean very similar to, for example, statins or anti-hypertensive blood pressure medications, if you want lifelong effects, you have to keep on them lifelong.' Prof Easton was speaking at an event at the Cheltenham Science Festival discussing the growing use of weight loss drugs with neurophysiologist Dr Simon Cork and consultant endocrinologist and obesity expert Dr Tony Goldstone. Hundreds of thousands of people access weight-loss medication privately (PA) Dr Cork said the jabs have an important role to play in losing weight but are part of wider changes to diet and lifestyle. 'I think we have to understand that diet is always limited. People will tend to lose on average around 5% of their body weight on a diet,' he said. 'But you're hungry, you're miserable, you're tired, your wife hates you because you're so grumpy, you're not going to continue with that. 'But we should absolutely all be looking at our diet and all changing our diet, and doing something.' Dr Goldstone said weight loss drugs had been used in the treatment of diabetes for over a decade and had benefits of reducing the risk of developing other conditions. 'We're now in the third and fourth generation of these drugs, but the first generation of these drugs we've been using for 15 years for diabetes,' he said. 'There is nothing of concern that has emerged. In fact, all we're seeing are benefits. I'm not too worried about longer term side effects coming out. 'There is no real biological reason why there should be dangerous side-effects in the way that we know these drugs work. 'The benefits of the weight loss improvement in the diabetes are actually by themselves helping health and preventing other diseases, like cancer, heart attacks, renal failure, and potentially even reducing the risk of Alzheimer's disease. 'All those benefits, even if there was something that we hadn't really thought of that emerged down the line, I suspect that the harm of that is outweighed by the potential benefits of weight loss improvement in diabetes control.' Dr Cork said no drug is without side-effects and previous weight loss medications had failed because of them. 'There are side-effects, there are some concerning side-effects that tend to be very rare, but then you can monitor for those side-effects,' he said. 'As long as you're getting the correct care, as long as your GP is aware that you're taking them, then those should be identified. 'If you do find those side-effects, you can stop taking the drug.'
